Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight

Summary

Non-small cell lung cancer market is projected to grow at 6.6% CAGR through 2036, driven by advancements in targeted therapies, immune checkpoint inhibitors, and biomarker-driven treatment approaches. This is a market analysis article with no specific company or clinical trial data.